Table 1.
No EVD Group N=111 | EVD Group N=111 | P Value | |
---|---|---|---|
Patient-related Variables | |||
Male, n (%) | 59 (53%) | 60 (54%) | 0.83 |
Female, n (%) | 52 (47%) | 51 (46%) | |
Age, years | 62±13.6 | 61±15.6 | 0.97 |
Body mass Index [BMI] (kg/m2) | 26.9±5.3 | 26.6±4.8 | 0.81 |
Tumor-related Variables | |||
Histology, n (%): | |||
Well-differentiated | 3 (3%) | 7 (6%) | |
Moderately differentiated | 48 (43%) | 60 (54%) | 0.07 |
Poorly differentiated | 60 (54%) | 44 (40%) | |
Lauren classification, n (%): | |||
Intestinal | 48 (43%) | 58 (52%) | |
Mixed | 17 (15%) | 16 (14%) | 0.38 |
Diffuse | 46 (42%) | 37 (34%) | |
WHO classification, n (%) | |||
Tubular | 65 (59%) | 57 (51%) | |
Signet ring | 43 (39%) | 47 (42%) | 0.47 |
Other/unknown | 4 (4%) | 7 (6%) | |
Location, n (%): | |||
Lower third | 51 (46%) | 46 (41%) | |
Middle third | 34 (31%) | 29 (26%) | 0.32 |
Upper third | 26 (23%) | 36 (33%) | |
T status, n (%): | |||
T0 | 6 (5%) | 7 (6%) | |
T1a | 19 (17%) | 22 (20%) | |
T1b | 20 (18%) | 19 (17%) | |
T2 | 16 (14%) | 12 (11%) | 0.97 |
T3 | 30 (27%) | 31 (28%) | |
T4a | 18 (16%) | 19 (17%) | |
T4b | 2 (2%) | 1 (1%) | |
N status, n (%): | |||
N0 | 64 (58%) | 63 (57%) | |
N1 | 18 (16%) | 19 (17%) | 1.0 |
N2 | 13 (12%) | 13 (12%) | |
N3 | 16 (14%) | 16 (14%) | |
Stage, n (%): | |||
in situ | 6 (5%) | 6 (5%) | |
I | 47 (43%) | 45 (41%) | |
II | 29 (26%) | 31 (28%) | 0.98 |
III | 28 (25%) | 27 (24%) | |
IV | 1 (1%) | 2 (2%) | |
Treatment-related Variables | |||
Neoadjuvant Chemotherapy, n (%): | |||
Yes | 50 (45%) | 61 (55%) | 0.18 |
No | 61 (55%) | 50 (45%) | |
Total/Subtotal Gastrectomy, n (%) | 44 (40%) | 44 (40%) | 1.0 |
Distal Gastrectomy, n (%) | 67 (60%) | 67 (60%) | |
Lymphadenectomy, n (%): | |||
D1+ | 7 (6%) | 9 (8%) | 1.0 |
D2 | 104 (94%) | 102 (92%) |
WHO: World Health Organization